Wellington Management Group LLP cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 9.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 673,157 shares of the company's stock after selling 69,588 shares during the period. Wellington Management Group LLP owned about 1.39% of Axsome Therapeutics worth $56,956,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Assetmark Inc. acquired a new stake in Axsome Therapeutics in the fourth quarter worth $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics during the fourth quarter worth $64,000. KBC Group NV raised its holdings in shares of Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after acquiring an additional 385 shares during the period. Xponance Inc. raised its holdings in shares of Axsome Therapeutics by 11.6% during the fourth quarter. Xponance Inc. now owns 2,659 shares of the company's stock worth $225,000 after acquiring an additional 277 shares during the period. Finally, Intrust Bank NA raised its holdings in shares of Axsome Therapeutics by 6.9% during the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company's stock worth $239,000 after acquiring an additional 183 shares during the period. 81.49% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the stock. HC Wainwright restated a "buy" rating and set a $200.00 price objective on shares of Axsome Therapeutics in a report on Thursday, April 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price target on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, April 1st. William Blair reiterated an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Finally, Mizuho lifted their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $169.80.
Read Our Latest Stock Report on Axsome Therapeutics
Axsome Therapeutics Stock Performance
NASDAQ AXSM traded down $6.55 during trading on Thursday, reaching $95.12. The company's stock had a trading volume of 170,008 shares, compared to its average volume of 674,574. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The firm has a market capitalization of $4.64 billion, a price-to-earnings ratio of -16.03 and a beta of 0.88. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The firm has a 50 day moving average price of $120.05 and a 200 day moving average price of $101.90.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. As a group, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Insider Activity
In other news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 22.40% of the company's stock.
About Axsome Therapeutics
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
